HapOnco Breast Cancer 21-Gene Detection

Genetic screening for hereditary cancer susceptibility genes including BRCA and other tumor suppressors. This test enables early identification of high-risk individuals for surveillance.

In vitro diagnostic test for identifying and quantifying cancer-related biomarkers. Supports oncology diagnosis, prognosis, and treatment monitoring.

A high-throughput drug sensitivity testing platform utilizing renewable primary cancer cells to predict treatment response. This service enables personalized treatment selection through comprehensive chemotherapy and targeted drug profiling.

Blood test panel for detecting and characterizing genetic and epigenetic mutations in circulating tumor DNA. Helps determine cancer origin, measure tumor burden, and identify new mutations during targeted therapy treatment.

A diagnostic kit based on GENETRON's proprietary 'one-step method' technology enabling completion of library construction in 1.5 to 3 hours (China patent ZL 201710218529.4). It detects EGFR, KRAS, BRAF, HER2, and PIK3CA gene mutations in DNA and ALK and ROS1 gene fusions in RNA from FFPE tissue samples of non-small cell lung cancer patients, as well as MET gene 14 exon skipping mutations.

In vitro diagnostic kit for detecting EGFR gene mutations in patient samples. Enables molecular profiling of epidermal growth factor receptor status to guide targeted cancer therapy selection and treatment planning in oncology.

Ultra-high sensitivity early detection kit designed to identify cancer gene mutations. Enables early-stage cancer diagnosis through advanced genetic analysis technology.

Diagnostic kits for detection and quantification of tumor-associated markers for oncology applications. Supports cancer screening, diagnosis, and treatment monitoring in clinical practice.

Specialized kit for HER2 gene amplification detection using FISH or IHC methodology in breast cancer diagnosis. The test enables identification of HER2-positive tumors for targeted therapy.

A diagnostic test for detecting tumor markers in patient samples. This test is used in oncology screening and monitoring.

A series of RNA-based diagnostic tests designed for early cancer screening and detection. These tests support the identification of cancer biomarkers for early intervention and patient management.

CRISPR-based molecular diagnostic test for tumor detection utilizing proprietary isothermal amplification and microfluidic integration. Enables rapid point-of-care testing with high sensitivity and specificity for oncology screening and monitoring applications.